major glp 1 drugs GLP-1 Receptor Agonist Shortage: Challenges and Solutions in Type 2 Diabetes Care Can one drug do it
Description
October 2024 The GLP-1 receptor agonist drug class has revolutionized obesity treatment, and has spurred investment and innovation across the pharmaceutical industry
Clinical studies, such as the STEP trials, have shown that adults using semaglutide GLP-1 at the recommended dose (2.4 mg weekly) can lose an average of about 15% of their initial body weight over 68 weeks when combined with healthy lifestyle changes
The Human Side of the GLP-1 Divide Numbers only tell part of the story
For instance, Driver Favorable Policies The major growth factor of the GLP-1 receptor agonist market is the favorable government policies to combat diabetes and obesity
The closer to the center a drug is, the closer to launch
